The U.S. Food and Drug Administration has revoked the Emergency Use Authorization for bamlanivimab administered alone, bamlanivimab and etesevimab administered together, and REGEN-COV. The agency authorized revised fact sheets for health care providers to include additional information on susceptibility of SARS-CoV-2 variants to each of the monoclonal antibody therapies that are available through an Emergency Use Authorization for the treatment of COVID-19. The FDA said it is providing this information to equip health care providers with the most current data so they can make informed decisions and provide appropriate care to patients with COVID-19. Among the makers of these treatments are Eli Lilly’s (LLY), AbCellera (ABCL), Vir Biotechnology (VIR), GSK (GSK) and Regeneron (REGN).
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Resmed Stock Sees Alarming Drop Alongside a New Obstructive Sleep Apnea Treatment Rival
- Eli Lilly Stock Jumps on FDA Approval of Obstructive Sleep Apnea Treatment
- Eli Lilly announces FDA approval for Zepbound for obstructive sleep apnea
- Eli Lilly announces FDA approval for Zepbound
- BMO lowers Novo Nordisk price target to $105, says reaction to data ‘overdone’